Eligibility for lecanemab treatment in a French memory clinic setting
{{output}}
Introduction: Anti-amyloid monoclonal antibodies, including lecanemab and donanemab, are now available for the treatment of Alzheimer's disease (AD). Defining real-world patient eligibility and identifying barriers to access are... ...
